Related Experiment Video
Updated: Apr 27, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
1.0K
Current regimens and novel agents for mantle cell lymphoma
Yiming Chen1, Michael Wang, Jorge Romaguera
1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
British Journal of Haematology
|July 1, 2014
Summary
Mantle cell lymphoma, a type of non-Hodgkin lymphoma, remains incurable despite conventional treatments. Novel targeted therapies, including ibrutinib, show promise and are being integrated into treatment regimens to improve patient outcomes.
Area of Science:
- Hematology
- Oncology
- Translational Research
Background:
- Mantle cell lymphoma (MCL) is a heterogeneous non-Hodgkin lymphoma subtype with limited curative options.
- Current treatments like immunochemotherapy and stem cell transplantation improve outcomes but do not offer a cure.
- Understanding MCL pathogenesis has led to the development of novel targeted agents.
Purpose of the Study:
- To review recent advances in mantle cell lymphoma treatment.
- To highlight the efficacy of novel therapeutic agents in clinical trials.
- To discuss the integration of novel agents into existing treatment paradigms.
Main Methods:
- Review of recent clinical trial data for novel MCL therapies.
- Analysis of preliminary results for agents targeting specific pathways.
- Examination of ongoing studies integrating novel agents with conventional therapy.
Main Results:
- Novel agents including bortezomib, lenalidomide, idelalisib, and ibrutinib have been developed.
- Preliminary clinical trial data, particularly for ibrutinib, demonstrate significant efficacy.
- These agents represent a new frontier in MCL treatment strategies.
Conclusions:
- Novel targeted therapies offer new hope for treating mantle cell lymphoma.
- Ibrutinib and other agents show promising efficacy in early studies.
- Integration of these novel agents into standard care may improve long-term outcomes for MCL patients.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
01:15Differentiation of Common Myeloid Progenitor Cells
3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:16Primary Lymphoid Organs
9.6K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
9.6K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K